Top

Published in:

Open Access 01-11-2013 | Original Article

CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34

Authors: Yasuyoshi Miyata, Yuji Sagara, Shin-ichi Watanabe, Akihiro Asai, Tomohiro Matsuo, Kojiro Ohba, Tomayoshi Hayashi, Hideki Sakai

Published in: Virchows Archiv | Issue 5/2013

Abstract

Angiogenesis plays an important role in cancer progression in many types of cancer. Evaluation of angiogenesis is often performed, but the optimal methodology for human cancer has not been agreed upon. As adequate evaluation of angiogenesis in cancer tissues might be important for prediction of prognosis and treatment decisions, we evaluated angiogenesis semiquantitatively by assessing microvessel density (MVD) in urothelial cancer of the upper urinary tract (UC-UUT). We compared the performance of three endothelial cell markers (CD31, CD34, and CD105) on formalin-fixed tissues from 122 patients diagnosed with UC-UUT without metastasis. Vascular endothelial growth factor (VEGF)-A expression was also evaluated immunohistochemically. Correlations between MVD with each marker and pT stage, grade, survival, and VEGF-A expression were investigated. Mean (standard deviation) MVD as estimated by immunohistochemical staining with anti-CD31, anti-CD34, and anti-CD105 were 47.1 (17.9)/high-power field (HPF), 70.9 (19.5)/HPF, and 31.2 (16.7)/HPF, respectively. Although all MVDs were significantly associated with pT stage and grade, CD105-MVD showed the strongest association. Similarly, CD105-MVD showed the strongest correlation with VEGF-A expression (r = 0.530, p < 0.001). Although all MVDs were associated with metastasis-free survival and cause-specific survival on univariate analysis, only CD105-MVD was retained as an independent predictor in multivariate analysis including pT stage and grade. CD105-MVD may be the preferred marker for semiquantitative assessment of angiogenesis in patients with UC-UUT.

Folkman J (1990) What is the evidence that tumors are angiogenesis dependent? J Natl Cancer Inst 82(1):4–6PubMedCrossRef

Stein JP, Lieskovsky G, Cote R, Groshen S, Feng AC, Boyd S et al (2001) Radical cystectomy in the treatment of invasive bladder cancer: long-term results in 1,054 patients. J Clin Oncol 19(3):666–675PubMed

Inoue K, Kamada M, Slaton JW, Fukata S, Yoshikawa C, Tamboli P et al (2002) The prognostic value of angiogenesis and metastasis-related genes for progression of transitional cell carcinoma of the renal pelvis and ureter. Clin Cancer Res 8(6):1863–1870PubMed

Miyata Y, Kanda S, Ohba K, Nomata K, Hayashida Y, Eguchi J et al (2006) Lymphangiogenesis and angiogenesis in bladder cancer: prognostic implications and regulation by vascular endothelial growth factor-A, -C, and –D. Clin Cancer Res 12(3 Pt 1):800–806PubMedCrossRef

Shariat SF, Youssef RF, Gupta A, Chade DC, Karakiewicz PI, Isbarn H et al (2010) Association of angiogenesis-related markers with bladder cancer outcomes and other molecular markers. J Urol 183(5):1744–1750PubMedCrossRef

Chabannes E, Bernardini S, Wallerrand H, Bittard H (2001) Angiogenesis in bladder: prognosis indicator and therapeutic target. Prog Urol 11(3):417–427PubMed

Herrmann E, Bögemann M, Bierrer S, Eltze E, Toma MI, Köpke T et al (2007) The role of the endothelin axis and microvessel density in bladder cancer—correlation with tumor angiogenesis and clinical prognosis. Oncol Rep 18(1):133–138PubMed

Yao Y, Kubota T, Takeuchi H, Sato K (2005) Prognostic significance of microvessel density determined by anti-Cd105/endoglin monoclonal antibody in astrocytic tumors: comparison with an anti-CD31 monoclonal antibody. Nephropathology 25(3):201–206CrossRef

Yao Y, Pan Y, Chen J, Sun X, Qiu Y, Ding Y (2007) Endoglin (CD105) expression in angiogenesis of primary hepatocellular carcinoma: analysis using tissues microarray and comparison with CD34 and VEGF. Ann Clin Lab Sci 37(1):39–48PubMed

10.

da Silva BB, Lopes-Costa PV, dos Santos AR, de Sousa-Júnior EC, Alencar AP, Pires CG et al (2009) Comparison of three vascular endothelial markers in the evaluation of microvessel density in breast cancer. Eur J Gynecol Oncol 30(3):285–288

11.

Randall LM, Monk BJ, Darcy KM, Tian C, Burger RA, Liao SY et al (2009) Markers of angiogenesis in high-risk, early-stage cervical cancer: a Gynecologic Oncology Group Study. Gynecol Oncol 112(3):583–589PubMedCrossRef

12.

Rubatt JM, Darcy KM, Hutson A, Bean SM, Havrilesky LJ, Grace LA et al (2009) Independent prognostic relevance of microvessel density in advanced epithelial ovarian cancer and associations between CD31, CD105, p53 status, and angiogenic marker expression: a gynecologic oncology group study. Gynecol Oncol 112(3):469–474PubMedCrossRef

13.

Kumar S, Ghellal A, Li C, Byrne G, Haboubi N, Wang JM et al (1999) Breast carcinoma: vascular density determined using CD105 antibody correlates with tumor prognosis. Cancer Res 59(4):856–861PubMed

14.

Tanaka F, Otake Y, Yanagihara K, Kawano Y, Miyahara R, Li M et al (2001) Evaluation of angiogenesis in non-small cell lung cancer: comparison between anti-CD34 antibody and anti-CD105 antibody. Clin Cancer Res 7(11):3410–3415PubMed

15.

Friedrich MG, Toma MI, Petri S, Huland H (2003) Cyclooxygenase-2 promotes angiogenesis in pTa/T1 urothelial bladder carcinoma but does not predict recurrence. BJU Int 92(4):389–392PubMedCrossRef

16.

Friedrich MG, Toma MI, Petri S, Cheng JC, Hammerer P, Erbersdobler A et al (2004) Expression of maspin in non-muscle invasive bladder carcinoma: correlation with tumor angiogenesis and prognosis. Eur Urol 45(6):737–743PubMedCrossRef

17.

Miyata Y, Koga S, Takehara K, Kanetake H, Kanda S (2003) Expression of thrombospondin-derived 4N1K peptide-containing proteins in renal cell carcinoma tissues is associated with a decrease in tumor growth and angiogenesis. Clin Cancer Res 9(5):1734–1740PubMed

18.

Iwata T, Miyata Y, Kanda S, Nishikido M, Hayashi T, Sakai H et al (2008) Lymphangiogenesis and angiogenesis in conventional renal cell carcinoma: association with vascular endothelial growth factors A to D immunohistochemistry. Urology 71(4):749–754PubMedCrossRef

19.

Fonsatti E, Altomonte M, Nicotra MR, Natali PG, Maio M (2003) Endoglin (CD105): a powerful therapeutic target on tumor-associated angiogenic blood vessels. Oncogene 22(42):6557–6563PubMedCrossRef

20.

Brewer CA, Setterdahl JJ, Li MJ, Johnston JM, Mann JL, McAsey ME (2000) Endoglin expression as a measure of microvessel density in cervical cancer. Onset Gynecol 96(2):147–155

21.

Martone T, Rosso P, Albera R, Migliaretti G, Fraire F, Pignataro L et al (2005) Prognostic relevance of CD105+ microvessel density in HNSCC patients outcome. Oral Oncol 41(2):147–155PubMedCrossRef

22.

Deniz H, Karakök M, Yagcı F, Glüdür ME (2010) Evaluation of relationship between HIF-1α immunoactivity and stage, grade, angiogenic profile, and proliferative index in bladder urothelial carcinomas. Int Urol Nephrol 42(1):103–107PubMedCrossRef

23.

Weidner N, Semple JP, Welch WR, Folkman J (1991) Tumor angiogenesis and metastasis correlation in invasive breast cancer. N Engl J Med 324(1):1–8PubMedCrossRef

24.

Bodey B, Bodey B Jr, Siegel SE, Kaiser HE (1998) Overexpression of endoglin (CD105): a marker of breast cancer-induced neovascularization. Anticancer Res 18(5A):3621–3628PubMed

25.

Traweek ST, Kandalaft PL, Mehta P, Battifora H (1991) The human hematopoietic progenitor cell antigen (CD34) in vascular neoplasia. Am J Clin Pathol 96(1):25–31PubMed

26.

Van Netten JP, Cann SA, van der Weshuizen NG (1995) Angiogenesis and tumor growth. N Engl J Med 334(14):920–921

27.

Mineo TC, Ambrogi V, Baldi A, Rabitti C, Bollero P, Vincenzi B et al (2004) Prognostic impact of VEGF, CD31, CD34, and CD105 expression and tumor vessel invasion after radical surgery for IB-IIA non-small cell lung cancer. J Clin Pathol 57(6):591–597PubMedCrossRef

28.

Yang C-C, Chu K-C, Yeh W-M (2004) The expression of vascular endothelial growth factor in transitional cell carcinoma of urinary bladder is correlated with cancer progression. Urol Oncol 22(1):1–6PubMedCrossRef

29.

Yu JX, Zhang XT, Laio YQ, Zhang QY, Chen H, Lin M et al (2003) Relationship between expression of CD105 and growth factors in malignant tumors of gastrointestinal tract and its significance. World J Gastroenterol 9(12):2866–2869PubMed

30.

Erdem O, Taskiran C, Onan MA, Erdem M, Guner H, Ataoglu O (2006) CD105 expression is an independent predictor of survival in patients with endometrial cancer. Gynecol Oncol 103(3):1007–1011PubMedCrossRef

Title: CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34
Authors: Yasuyoshi Miyata
Yuji Sagara
Shin-ichi Watanabe
Akihiro Asai
Tomohiro Matsuo
Kojiro Ohba
Tomayoshi Hayashi
Hideki Sakai
Publication date: 01-11-2013
Publisher: Springer Berlin Heidelberg
Published in: Virchows Archiv / Issue 5/2013
Print ISSN: 0945-6317
Electronic ISSN: 1432-2307
DOI: https://doi.org/10.1007/s00428-013-1463-8

Keynote webinar | Spotlight on medication adherence

Springer Medicine

CD105 is a more appropriate marker for evaluating angiogenesis in urothelial cancer of the upper urinary tract than CD31 or CD34

Abstract

Keynote webinar | Spotlight on medication adherence

Springer Medicine

Abstract

Please log in to get access to this content

Other articles of this Issue 5/2013

Ultra-deep sequencing confirms immunohistochemistry as a highly sensitive and specific method for detecting BRAF V600E mutations in colorectal carcinoma

Early gallbladder carcinoma has a favorable outcome but Rokitansky–Aschoff sinus involvement is an adverse prognostic factor

Increased expression of Trop2 correlates with poor survival in extranodal NK/T cell lymphoma, nasal type

Co-expression of receptors of the HER family correlates with clinical outcome in non-small cell lung cancer (NSCLC)

Incidence and review of sessile serrated polyp reporting in a district general hospital in the UK

Idiopathic vs. secondary retroperitoneal fibrosis: a clinicopathological study of 12 cases, with emphasis to possible relationship to IgG4-related disease